What it's for (Indications)
- Sucralfate is primarily indicated for the short-term treatment (typically up to 8 weeks) of active duodenal ulcers.
- Its utility extends to the maintenance therapy of duodenal ulcers following successful healing, aimed at preventing recurrence.
- Beyond duodenal ulcers, sucralfate is also frequently employed in the management of gastric ulcers, particularly when acid suppression alone is insufficient or contraindicated, or when a mucosal protective agent is preferred.
- It is recognized for its role in the prophylaxis of stress ulcers in critically ill patients, where the gastric mucosa is highly vulnerable to erosions and bleeding due to physiological stress.
- Furthermore, sucralfate can be used for the treatment of gastroesophageal reflux disease (GERD), especially in cases presenting with esophageal erosions or reflux esophagitis, by forming a protective barrier over the inflamed mucosa.
- Its local protective properties also make it useful in managing stomatitis induced by radiation or chemotherapy, and radiation proctitis, providing localized protection and promoting healing within these mucosal tissues.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | For active duodenal ulcer, the recommended adult oral dosage is 1 g four times per day, taken on an empty stomach. Antacids may be used as needed for pain relief but should not be taken within 30 minutes before or after sucralfate. Treatment should be continued for 4 to 8 weeks unless healing has been demonstrated by x-ray or endoscopic examination. For maintenance therapy, the recommended adult oral dosage is 1 g twice a day. For elderly patients, dose selection should be cautious, usually starting at the low end of the dosing range, considering potential decreases in hepatic, renal, or cardiac function and concomitant medications. |
Safety & Warnings
Common Side Effects
- Adverse reactions to sucralfate are generally minor.
- The most frequent complaint is constipation (reported in 2% of patients).
- Other adverse effects reported in less than 0.
- 5% of patients include diarrhea, nausea, vomiting, gastric discomfort, indigestion, flatulence, dry mouth, pruritus, rash, dizziness, insomnia, sleepiness, vertigo, back pain, and headache.
- Post-marketing cases of hypersensitivity have been reported, including dyspnea, lip swelling, pruritus, rash, and urticaria.
- Severe reactions such as anaphylactic reactions, bronchospasm, laryngeal edema, edema of the mouth, pharyngeal edema, respiratory tract edema, and swelling of the face have also been reported.
- Bezoar formation has been observed.
Serious Warnings
- Black Box Warning: Sucralfate (Ulsanic) does not carry a formal FDA-mandated Black Box Warning. However, several serious warnings and precautions must be considered when prescribing or administering this medication to ensure patient safety, particularly given its potential for systemic absorption of aluminum and interaction with other medications. Healthcare providers should be acutely aware of the risks associated with aluminum accumulation, especially in patients with impaired renal function, and the potential for bezoar formation. Careful patient selection, monitoring, and counseling on appropriate administration are crucial to mitigate these significant risks. Adherence to prescribed dosages and awareness of potential drug-drug interactions are also paramount in preventing adverse outcomes.
- Caution is advised in patients with kidney impairments.
- For pregnant females, there is no evidence of risk, but sucralfate should be used only with a doctor's recommendation.
- In lactating females, caution is advised, and consultation with a doctor is recommended before use.
- Patients should avoid driving when taking this medicine as it may affect their ability to drive.
- Alcohol consumption should be avoided while on this medication.
- For elderly patients, dose selection should be cautious, generally starting at the lower end of the dosing range, due to the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.
- Cases of hypersensitivity reactions, including severe anaphylactic reactions, have been reported.
- Bezoar formation has been reported, particularly in critically ill patients, those with altered gastrointestinal motility, or those receiving concomitant enteral nutrition.
How it Works (Mechanism of Action)
Sucralfate is an oral gastrointestinal protective agent whose primary mechanism of action involves forming a protective barrier over ulcerated or eroded mucosal surfaces. Chemically, it is an aluminum salt of sulfated sucrose. Upon exposure to an acidic environment, specifically at pH levels below 4, sucralfate undergoes a process of polymerization and cross-linking. This reaction transforms the compound into a viscous, sticky, paste-like gel that selectively adheres to the positively charged proteinaceous exudates present at the base of ulcers and erosions. This preferential binding to damaged tissue, rather than intact mucosa, forms a strong, durable bond with the necrotic tissue. This adherent complex acts as a physical barrier, shielding the underlying damaged mucosa from further insult by gastric acid, pepsin, and bile salts. Unlike antacids or proton pump inhibitors, sucralfate does not neutralize gastric acid or directly reduce its secretion; instead, it provides a localized protective coating. Additionally, sucralfate is thought to exert cytoprotective effects by stimulating the local production of prostaglandins, which are known to enhance mucosal blood flow, bicarbonate secretion, and mucus production. It also adsorbs pepsin and bile acids, further reducing their damaging potential. Systemic absorption of sucralfate is minimal, with less than 5% of the orally administered dose typically absorbed, minimizing systemic side effects.